Main Article Content

Mohammad Sayyed Bakheet
Mohamed Ismail Seddik
Samir Kamal Abdul-Hamid Kotb
Asmaa Osman


Background: Methylenetetrahydrofolate reductase (MTHFR) is a regulatory enzyme of homocysteine (Hcy) metabolism. Point mutation in MTHFR and hyperhomocysteinemia (HHcy) are implicated in the pathogenesis of diabetic nephropathy (DN) in many ethnic groups. The aim of this study is to find if MTHFR C677T polymorphism is a risk factor of DN in types 2 diabetes mellitus (T2DM) patients. Patients and methods: The MTHFR C677T polymorphism was detected in 100 T2DM patients by PCR-RFLP. They were divided into three groups; 38 patients with normoalbuminuria, 33 patients with microalbuminuria and 29 patients with macroalbuminuria. Serum levels of homocysteine were determined by nephelometry. Results: The presence of MTHFR 677T allele increases the risk of macroalbuminuria 3.3 folds (p=0.009) in T2DM patients. The presence of mutant genotypes CT and TT increase the risk of macroalbuminuria 3 folds (p=0.019). Serum levels of HCY were associated with C677T mutation (p=0.02), also there was significant association between high levels of HCY and DN (p=0.014). Conclusion: Methylenetetrahydrofolate reductase (MTHFR) C677T gene mutation was associated with increased risk for overt diabetic nephropathy in type 2 diabetic patients and had effect on serum levels of homocysteine.

Key words: diabetic nephropathy- type 2 diabetes mellitus- homocysteine


Download data is not yet available.

Article Details

How to Cite
Sayyed Bakheet, M., Ismail Seddik, M., Abdul-Hamid Kotb, S. K., & Osman, A. (2016). ASSOCIATION BETWEEN MTHFR C677T GENE POLYMORPHISM AND DIABETIC NEPHROPATHY IN TYPE 2 DIABETES MELLITUS IN UPPER EGYPT. Innovat International Journal Of Medical & Pharmaceutical Sciences, 1(1), 26–33.


American Diabetes association "ADA", (2012): Diagnosis and classification of melltus, diabetes care 35, 64-S71.

AbdRaboh NR, Badr S, Ali S (2013): Prevalence of methylene-tetrahydrofolate reductase C677T and A1298C polymorphisms in Egyptian patients with type 2 diabetes mellitus, Egy J Medical Human Genetics 14, 87-93.

American Diabetes association "ADA", (2013): Standards of medical care, diabetes care 36(1), S11-66.

Taylor EN, Hu FB and Curhan GC (2006): Antihypertensive medications and the risk of incident type 2 diabetes, Diabetes Care29, 1065-1070.

Vigersky RA (2011): An overview of management issues in adult patients with type 2 diabetes mellitus. J Diabetes Sci Technol,5(2): 245–250.

Hovind P, Tarnow L, Rossing P, Jensen BR, Graae M, Torp I, Binder C, Parving HH (2004): Predictors of the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. Brit. med. j. 328:1105-1108.

Adler AI, Stevens RJ, Manley SE, Bilous WR, Cull AC, Holman RR (2003): Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney int. 225-232.

Conway BR, and Maxwell AP (2009): Genetics of diabetic nephropathy: are there clues to the understanding of common kidney diseases?, Nephron Clin Pract112, c213-221.

Dronavalli S, Duka I, Bakris GL (2008): The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab ;4:444–452..

McCully, KS (2001): The biomedical significance of homocysteine, J. Sci. Exp. 15(1): 5-20.

Ramakrishnan S, Prasannan KG and Rajan R (2001): Text Book of Biochemistry, 3rd edn, p. 289, Orient Longman, Chennai

Chambers, JC, Seddon, MD, Shah, S, and Kooner, JS (2001): Homocysteine--a novel risk factor for vascular disease, J R Soc Med94, 10-13.

Huang YC, Chang SJ, Chiu YT, Chang HH, Cheng CH. (2003): The status of plasma homocysteine and related B-vitamins in healthy young vegetarians and nonvegetarians. Eur J Nutr ;42:84-90.

Lominadze, D., Roberts, AM, Tyagi, N, Moshal, KS, and Tyagi, SC (2006): Homocysteine causes cerebrovascular leakage in mice, Am J Physiol Heart Circ Physiol290, H1206-1213.

Mudd, SH, Finkelstein, JD, Refsum, H, et al., (2000): Homocysteine and its disulfide derivatives: a suggested consensus terminology, Arterioscler Thromb Vasc Biol20, 1704-1706.

Friedman, AN, Bostom, AG, Selhub, J, Levey, AS, and Rosenberg, IH (2001): The kidney and homocysteine metabolism, J Am Soc Nephrol12, 2181-2189.

Igari, S, Ohtaki, A, Yamanaka, Y, Sato, Y, Yohda, Odaka, M, Noguchi, K, and Yamada, K (2011): Properties and crystal structure of methylenetetrahydrofolate reductase from Thermus thermophilus HB8, PLoS One6, e23716.

Haiyan C, Fang W, Lihua W ., (2015): MTHFR gene C677T polymorphism and type 2 diabetic nephropathy in Asian populations: a meta-analysis. Int J Clin Exp Med; 8(3):3662-3670.

Ramakrishnan S, Sulochana KN, Lakshmi S et al., (2006): Biochemistry of homocysteine in health and diseases Indian Journal of Biochemistry & Biophysics Vol. 43, pp. 275-283

20-Philippe D, Michel P, Nadine L, Suzanne LC, and Denis B (2001): Impaired Homocysteine Metabolism and Atherothrombotic Disease. Laboratory Investigation; Vol. 81, No. 5, p. 645.

Goyette P, Sumner JS, Milos R, Duncan AM, Rosenblatt DS, Matthews RG, and Rozen R (1994): Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification, Nat Genet7, 195-200.

Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA and van den Heuvel LP. (1995): A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase, Nat Genet10, 111-113.

Homberger A, Linnebank M, Winter C, Willenbring H, Marquardt T, Harms E, and Koch HG (2000): Genomic structure and transcript variants of the human methylenetetrahydrofolate reductase gene, Eur J Hum Genet8, 725-729.

Morel CF, Scott P, Christensen E, Rosenblatt DS, and Rozen R (2005): Prenatal diagnosis for severe methylenetetrahydrofolate reductase deficiency by linkage analysis and enzymatic assay, Mol Genet Metab 85, 115-120.

Van der Put NM, Gabreels F, Stevens, EM, Smeitink JA, Trijbels FJ, Eskes TK, van den Heuvel LP, and Blom HJ (1998): A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects, Am J Hum Genet62, 1044-1051.

Yamada K, Chen Z, Rozen R, and Matthews RG (2001): Effects of common polymorphisms on the properties of recombinant human methylene-tetrahydrofolate reductase, Proc Natl Acad Sci U S A98, 14853-14858.

Weisberg IS, Jacques PF, Selhub J, Bostom AG, Chen Z, et al. (2001): The 1298A–.C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. Atherosclerosis 156: 409–415.

Franco RF, and Reitsma PH (2001): Genetic risk factors of venous thrombosis, Hum Genet109, 369-384.

Leclerc D, and Rozen R (2007): Molecular genetics of MTHFR: polymorphisms are not all benign, Med Sci (Paris)23, 297-302.

Botto LD, and Yang Q (2000): 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review, Am J Epidemiol151, 862-877.

Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, and Rozen R (1996): Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations, Circulation93, 7-9.

Trinder P. (1969): Determination of blood glucose using glucose oxidase with an alternative oxygen acceptor, Ann Clin Biochem 6, 24-27.

Bunn HF, Gabbay KH, and Gallop PM (1978): The glycosylation of hemoglobin: relevance to diabetes mellitus, Science200, 21-27.

Foster-Swanson A, Swartzentruber M, and Roberts P. (1994): Reference interval studies of the rate-blanked creatinine/Jaffe method on BM/Hitachi systems in six U.S. laboratories. Clin. Chem., 40: 1057.

Allain CC, Poon LS, Chan CS, Richmond W and Fu PC (1974): Enzymatic determination of total serum cholesterol, Clin Chem20, 470-475.

Lopes-Virella MF, Stone P, Ellis S, and Colwell JA (1977): Cholesterol determination in high-density lipoproteins separated by three different methods, Clin Chem23, 882-884.

Friedewald WT, Levy RI, Fredrickson DS (1972): Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the prearative ultracentrifuge. Clin. Chem., 18:499–502.

McGowan MW, Artiss JD, Strandbergh DR, and Zak B (1983): A peroxidase-coupled method for the colorimetric determination of serum triglycerides, Clin Chem29, 538-542.

39- Rowe DJ, Dawnay A, and Watts GF (1990): Microalbuminuria in diabetes mellitus: review and recommendations for the measurement of albumin in urine, Ann Clin Biochem27 (Pt 4), 297-312.

40- Frosst P, Blom HJ, Milos R, Goyette P, and et al., (1995): A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase, Nat Genet10, 111-113.

41- Yanling Wu, Yanping Ding, Yoshimasa Tanaka and Wen Zhang (2014): Risk Factors Contributing to Type 2 Diabetes and Recent Advances in the Treatment and Prevention, International Journal of Medical Sciences, 11(11):1185-1200.

42- Nielsen P, Bamberger SG, Stamhus j, et al., (2012): Capabilities for Innovation: The Nordic Model and Employee Participation. Nordic Journal of Working life studies;1:99.

Choudhury D, Tuncel M and Levi M. (2010): Diabetic nephropathy a multifaceted target of new therapies. Discov Med;10: 406-415.

Xuan X, Xiao-Kun L, Xiao X, et al., (2016): Association between MTHFR C677T polymorphism and diabetic nephropathy in the Chinese population: An updated meta-analysis and review. APSH, Nephrology 21;5-12.

Sen U and Tyagi SC. (2010): Homocysteine and Hypertension in Diabetes: Does PPARgamma have a regulatory role? PPAR Res;2010: 806538.

Sabanayagam C and Shankar A. (2011): Association between plasma homocysteine and microalbuminuria in persons without hypertension, diabetes mellitus, and cardiovascular disease. Clin Exp Nephrol; 15: 92-99.

47- Parvanova A, Iliev I, Dimitrov BD, et al., (2002): Hyperhomocyteinemia and increased risk of retinopathy: a cross-sectional, case-control study in patients with type 2 diabetes (Letter). Diabetes Care 25: 2361, 2002.20.

Noiri E., Taguchi J.I., Nakao A., Fujita T. (2000): MTHFR gene polymorphism as an exacerbation factor of diabetic nephropathy in type 2 diabetes. Analysis in Japanese male hemodialysis patients. Diabetes Care; 23: 260.

49- Ukinc, K., Ersoz, H.O., Karahan, C., Erem, C., Eminagaoglu, S., Hacihasanoglu, A.B., Yilmaz, M., and Kocak, M. (2009): Methyltetrahydrofolate reductase C677T gene mutation and hyperhomocysteinemia as a novel risk factor for diabetic nephropathy, Endocrine36, 255-261.

Moczulski, D., Fojcik, H., Zukowska-Szczechowska, E., Szydlowska, I., and Grzeszczak, W. (2003): Effects of the C677T and A1298C polymorphisms of the MTHFR gene on the genetic predisposition for diabetic nephropathy, Nephrol Dial Transplant18, 1535-1540.

Rahimi, M., Hasanvand, A., Rahimi, Z., Vaisi-Raygani, A., Mozafari, H., Rezaei, M., Zargooshi, J., Najafi, F., and Shakiba, E. (2010): Synergistic effects of the MTHFR C677T and A1298C polymorphisms on the increased risk of micro- and macroalbuminuria and progression of diabetic nephropathy among Iranians with type 2 diabetes mellitus, Clin Biochem43, 1333-1339.

El-Baz, R., Settin, A., Ismaeel, A., Khaleel, A.A., Abbas, T., Tolba, W., Abd Allah, W., and Sobh, M.A. (2012): MTHFR C677T, A1298C and ACE I/D polymorphisms as risk factors for diabetic nephropathy among type 2 diabetic patients, J Renin Angiotensin Aldosterone Syst13, 472-477.

Huan W, Kai C, Ke X, Shixin X (2015): Association between plasma homocysteine and progression of early nephropathy in type 2 diabetic patients, Int J Clin Exp Med;8(7):11174-11180.

Mtiraoui, N., Ezzidi, I., Chaieb, M., Marmouche, H., Aouni, Z., Chaieb, A., Mahjoub, T., Vaxillaire, M., and Almawi, W.Y. (2007): MTHFR C677T and A1298C gene polymorphisms and hyperhomocysteinemia as risk factors of diabetic nephropathy in type 2 diabetes patients, Diabetes Res Clin Pract 75, 99-106.

Nemr, R., Salman, R.A., Jawad, L.H., Juma, E.A., Keleshian, S.H., and Almawi, W.Y. (2010): Differential contribution of MTHFR C677T variant to the risk of diabetic nephropathy in Lebanese and Bahraini Arabs, Clin Chem Lab Med48, 1091-1094.

Sharaf SM, Gawish HH and Elsherbiny EM (2012): Methylenetetrahydrofolate reductase (Mthfr C677t) gene polymorphism effect on development of diabetic nephropathy in Egyptian patients with type 2 daibetes mellitus. Life sci J; 9(2);874-880

Eroglu, Z., Erdogan, M., Tetik, A., Karadeniz, M., Cetinalp, S., Kosova, B., Gunduz, C., Ozgen, A.G., and Yilmaz, C. (2007): The relationship of the methylenetetrahydrofolate reductase C677T gene polymorphism in Turkish type 2 diabetic patients with and without nephropathy, Diabetes Metab Res Rev23, 621-624.

Sreenivas RA, Meera S, Ebenezer W, et al., (2014): Correlation between glycemic control and lipid profile in type 2 diabetic patients: HbA1c as an indicatior of dyslipidemia. Asian J Pharm Clin Res, Vol 7, Issue2, 153-155.

Singh G. and Kumar A (2011): Relationship among HbA1c and Lipid Profile in Punajbi Type 2 Diabetic Population. Journal of Exercise Science and Physiotherapy, Vol.7, No.2: 99-102.

Goldberg IJ. (1996): Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res; 37: 693-707.

Khan H.A., Sobki S.H. and Khan S.A. (2007): Association between glycaemic control and serum lipids profile in type 2 diabetic patients: HbA1c predicts dyslipidaemia. Clin. Exp. Med 7:24-29.

Selvin E., Wattanakit K., Steffes M.W., Coresh J. and Sharrett A.R. (2006): HbA1c and peripheral arterial disease in diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care 29: 877-882.

Velibor A, Mirjana D, Zoran S, Vladimir S, et al., (2013): Determining the relation between homocysteinemia and biomarkers of inflammation, oxidative stress and functional kidney status in patients with diabetic nephropathy. J Med Biochem 32:131-139.

Yang S, Zhang J, Feng C and Huang G (2013): MTHFR 677T variant contributes to diabetic nephropathy risk in Caucasian individuals with type 2 diabetes: a meta-analysis. Apr;(4):586-94.

Yoshioka K, Yoshida T, Umekawa T, Kogure A, Takakura Y, Toda H and Yoshikawa T. (2004): MTHFR gene polymorphism is not related to diabetic nephropathy in Japanese Type 2 diabetic patients. Diabet Med; 21:1051-1052.

Maeda M, Yamamoto I, Fukuda M, Motomura T, Nishida M, Nonen S, Fujio Y, Kasayama S and Azuma J. (2008): MTHFR gene polymorphism is susceptible to diabetic retinopathy but not to diabetic nephropathy in Japanese type 2 diabetic patients. J Diabetes Complications; 22: 119-125.

Lin R, Wang CN, Liu XM (2009): Matched case-control study on the association between polymorphism of MTHFR gene and diabetic nephropathy in type 2 diabetic patients. Mod. Prev. Med.; 36: 3801–4 .

Chang W, Zhang L, Yao Y et al., (2013): MTHFR C677T polymorphism and susceptibility to diabetic nephropathy in Chinese type 2 diabetic patients: a meta-analysis. Ren Fail, 35(7): 1038-1043.

Sun J, Xu Y, Zhu Y, Lu H. (2004): Genetic polymorphism of methylenetetrahydrofolate reductase as a risk factor for diabetic nephropathy in Chinese type 2 diabetic patients. Diabet. Res. Clin. Pract; 64: 185–90.

Helfenstein T., Fonseca, FA., Relvas, W. (2005): Prevalence of myocardial infarction is related to hyperhomocysteinemia but not influenced by C677T methylenetetrahydrofolate reductase and A2756G methionine synthase polymorphisms in diabetic and non-diabetic subjects, Clin Chim Acta355, 165-172.